Alpha Tau is nearing a major milestone with promising data expected soon for its Alpha DaRT treatment targeting glioblastoma multiforme (GBM) and pancreatic cancer. Notably, two of the first three GBM patients treated achieved a complete response, a rare outcome for this aggressive cancer. The company remains underrecognized by investors, suggesting potential for significant stock re-rating as these clinical results become public. This locally-administered alpha radiation therapy represents a unique approach in oncology.
KNOT Offshore Partners LP reported strong Q2 2026 results, beating analyst expectations with an EPS of $0.10 versus an estimated loss of $0.03 and revenue of $96.78 million exceeding forecasts. The company maintained a high shuttle tanker fleet utili...
Alphabet CEO Sundar Pichai told employees that Waymo, the company's self-driving car unit, could start making a meaningful financial contribution as soon as 2027. This suggests that Alphabet's investment in autonomous driving technology may be closer...
Mama's Creations reported a strong Q2 fiscal 2027 with revenue up 55% to $54.6 million and net income doubling to $2.6 million. The company’s growth is driven by new product launches, effective cross-selling, and inclusion in Costco's national mailer...
The Vanguard Total Bond Market ETF (BND) currently offers a higher yield than the Vanguard Short-Term Bond ETF (BSV), attracting income-focused investors. However, BND carries significantly more rate risk due to its longer duration and exposure to mo...
Owlet reported a record Q2 revenue of $33.9 million, up 29.9% year-over-year, driven by subscription growth and a rebound in gross margin to 54%. The company maintained its 2026 guidance, expecting $120 million in revenue and $8 million in EBITDA, wi...
